| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| L Trabace, T Cassano, R Cagiano, M Tattoli, C Pietra, L Steardo, K M Kendrick, V Cuom. Effects of ENA713 and CHF2819, two anti-Alzheimer's disease drugs, on rat amino acid levels. Brain research. vol 910. issue 1-2. 2001-10-25. PMID:11489269. |
these results suggest that the modulation of amino acidergic transmission could represent an additional mechanism of action in alzheimer's disease for some acetylcholinesterase inhibitors. |
2001-10-25 |
2023-08-12 |
rat |
| M R Farlo. Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine. Clinical therapeutics. vol 23 Suppl A. 2001-09-27. PMID:11396867. |
although no pharmacologic treatments have been proved to alter the pathology of alzheimer's disease, acetylcholinesterase inhibitor (achei) therapy offers symptomatic improvements in or delays in the progression of cognitive, behavioral, and functional deficits. |
2001-09-27 |
2023-08-12 |
Not clear |
| L Rasmusen, B Yan, A Robillard, F Dunba. Effects of washout and dose-escalation periods on the efficacy, safety, and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials. Clinical therapeutics. vol 23 Suppl A. 2001-09-27. PMID:11396868. |
with the increasing number of acetylcholinesterase inhibitors (acheis) being marketed for the treatment of alzheimer's disease (ad), physicians will need protocols for discontinuing one achei and initiating another ("switching"). |
2001-09-27 |
2023-08-12 |
Not clear |
| S H Ferri. Switching previous therapies for Alzheimer's disease to galantamine. Clinical therapeutics. vol 23 Suppl A. 2001-09-27. PMID:11396869. |
acetylcholinesterase inhibitors (acheis) are the most frequently prescribed drugs for the treatment of alzheimer's disease (ad). |
2001-09-27 |
2023-08-12 |
Not clear |
| P Camps, El Achab R, J Morral, D Muñoz-Torrero, A Badia, J E Baños, N M Vivas, X Barril, M Orozco, F J Luqu. New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. Journal of medicinal chemistry. vol 43. issue 24. 2001-08-23. PMID:11101357. |
new tacrine-huperzine a hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of alzheimer's disease. |
2001-08-23 |
2023-08-12 |
human |
| J Zhou, Y Fu, X C Tan. Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation. Neuroscience letters. vol 306. issue 1-2. 2001-08-16. PMID:11403956. |
huperzine a (hupa) and donepezil, two novel selective acetylcholinesterase inhibitors available for alzheimer's disease, were tested for their ability to alleviate injury from oxygen-glucose deprivation (ogd) in the rat pheochromocytoma line pc12 cells. |
2001-08-16 |
2023-08-12 |
rat |
| B Zöller, C Hock, H U Kul. [Rational therapy of Alzheimer dementia based on current clinical studies]. Praxis. vol 90. issue 19. 2001-08-09. PMID:11407240. |
based on the documentation presented here, only the approved acetylcholinesterase inhibitors are currently to be recommended under strict scientific criteria for use in the treatment of alzheimer's dementia. |
2001-08-09 |
2023-08-12 |
Not clear |
| M Tsolaki, T Pantazi, A Kazi. Efficacy of acetylcholinesterase inhibitors versus nootropics in Alzheimer's disease: a retrospective, longitudinal study. The Journal of international medical research. vol 29. issue 1. 2001-07-19. PMID:11277345. |
efficacy of acetylcholinesterase inhibitors versus nootropics in alzheimer's disease: a retrospective, longitudinal study. |
2001-07-19 |
2023-08-12 |
Not clear |
| M Tsolaki, T Pantazi, A Kazi. Efficacy of acetylcholinesterase inhibitors versus nootropics in Alzheimer's disease: a retrospective, longitudinal study. The Journal of international medical research. vol 29. issue 1. 2001-07-19. PMID:11277345. |
the aim of this study was to investigate the efficacy of nootropics (piracetam, aniracetam, nimodopine and dihydroergicristine) versus acetylcholinesterase inhibitors (ache-is) (tacrine and donepezil) in the treatment of alzheimer's disease. |
2001-07-19 |
2023-08-12 |
Not clear |
| N E Slatkin, M Rhiner, T M Bolto. Donepezil in the treatment of opioid-induced sedation: report of six cases. Journal of pain and symptom management. vol 21. issue 5. 2001-07-05. PMID:11369163. |
donepezil, an oral acetylcholinesterase inhibitor approved for the treatment of alzheimer's disease, was given to 6 cancer pain patients having sedation related to the analgesic use of opioids. |
2001-07-05 |
2023-08-12 |
Not clear |
| J E Lachowicz, R A Duffy, V Ruperto, J Kozlowski, G Zhou, J Clader, W Billard, H Binch, G Crosby, M Cohen-Williams, C D Strader, V Coffi. Facilitation of acetylcholine release and improvement in cognition by a selective M2 muscarinic antagonist, SCH 72788. Life sciences. vol 68. issue 22-23. 2001-06-21. PMID:11392630. |
current treatment of alzheimer's disease (ad) requires acetylcholinesterase inhibition to increase acetylcholine (ach) concentrations in the synaptic cleft. |
2001-06-21 |
2023-08-12 |
human |
| P Davidsson, K Blennow, N Andreasen, B Eriksson, L Minthon, C Hess. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neuroscience letters. vol 300. issue 3. 2001-06-14. PMID:11226635. |
differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with alzheimer's disease. |
2001-06-14 |
2023-08-12 |
Not clear |
| P Davidsson, K Blennow, N Andreasen, B Eriksson, L Minthon, C Hess. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neuroscience letters. vol 300. issue 3. 2001-06-14. PMID:11226635. |
the clinical significance and the effects of pharmacological treatment of patients with alzheimer's disease (ad) were evaluated by measurement of acetylcholinesterase (ache) in the cerebrospinal fluid (csf). |
2001-06-14 |
2023-08-12 |
Not clear |
| H Ogura, T Kosasa, Y Kuriya, Y Yamanish. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods and findings in experimental and clinical pharmacology. vol 22. issue 8. 2001-06-14. PMID:11256231. |
this study was designed to compare the in vitro inhibitory effects on acetylcholinesterase (ache) and butyrylcholinesterase (buche) of donepezil and some other cholinesterase (che) inhibitors which have been developed for the treatment of alzheimer's disease. |
2001-06-14 |
2023-08-12 |
Not clear |
| N D Volkow, Y S Ding, J S Fowler, S J Gatle. Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia. Biological psychiatry. vol 49. issue 3. 2001-06-07. PMID:11230872. |
positron emission tomography is a medical imaging method that can be used to measure the concentration, kinetics, and distribution of cholinergic-enhancing drugs directly in the human brain and assess the effects of the drugs at markers of cholinergic cell viability (vesicular transporters, acetylcholinesterase), at muscarininc and nicotinic receptors, at extracellular acetylcholine, at markers of brain function (glucose metabolism and blood flow), and on amyloid plaque burden in vivo in the brains of patients with alzheimer's disease. |
2001-06-07 |
2023-08-12 |
human |
| J Coyle, P Kersha. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biological psychiatry. vol 49. issue 3. 2001-06-07. PMID:11230880. |
despite the proven efficacy of acetylcholinesterase inhibitors in alzheimer's disease, there is a need for new and more effective treatments. |
2001-06-07 |
2023-08-12 |
Not clear |
| J Coyle, P Kersha. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biological psychiatry. vol 49. issue 3. 2001-06-07. PMID:11230880. |
galantamine is a novel treatment for alzheimer's disease that inhibits acetylcholinesterase and modulates nicotinic receptors. |
2001-06-07 |
2023-08-12 |
Not clear |
| H C Dringenberg, P P Laporte, P Diavolitsi. Increased effectiveness of tacrine by deprenyl co-treatment in rats: EEG and behavioral evidence. Neuroreport. vol 11. issue 16. 2001-05-31. PMID:11095509. |
the acetylcholinesterase inhibitor tacrine and the monoamine oxidase inhibitor deprenyl are considered useful pharmacotherapies for alzheimer's disease (ad). |
2001-05-31 |
2023-08-12 |
rat |
| N R Dunn, G L Pearce, S A Shaki. Adverse effects associated with the use of donepezil in general practice in England. Journal of psychopharmacology (Oxford, England). vol 14. issue 4. 2001-05-31. PMID:11198060. |
donepezil is an acetylcholinesterase inhibitor indicated for the symptomatic treatment of mild to moderate alzheimer's disease. |
2001-05-31 |
2023-08-12 |
Not clear |
| J Sáez-Valero, D H Smal. Altered glycosylation of cerebrospinal fluid butyrylcholinesterase in Alzheimer's disease. Brain research. vol 889. issue 1-2. 2001-05-17. PMID:11166713. |
our previous studies have shown that a minor isoform of acetylcholinesterase (ache) is increased in the cerebrospinal fluid (csf) of alzheimer's disease (ad) patients. |
2001-05-17 |
2023-08-12 |
Not clear |